Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Efficacy and Safety of Thermic Devices in the Treatment of Meibomian Gland Dysfunction

NCT: NCT03767530 · RECRUITING

NCT IDNCT03767530
StatusRECRUITING
Start Date2019-09-01
Completion2027-12-20

Brief Summary

Dry eye syndrome is a common eye disease that affects 1 to 2 out of 10 persons around the planet. One common cause of this disease is the meibomian gland dysfunction. Meibomian glands are very small glands located at the rim of the eyelids that produce an oily substance that prevents the evaporation of tears. When these glands are compromised, the tear film evaporates quickly and the eyes dry up. This disease presents as eye irritation, foreign body sensation, inflammation, etc. The treatment of choice for MGD is eyelid massage and warm compresses 2 times a day. However, these treatments not always work perfectly, and as a result, patients find it hard to follow doctor's orders. Another kind of treatment is thermal therapy. There are several devices that are designed to apply heat on the eyelids, such as Lipiflow, MiBo Thermoflo, and Blephasteam. In this study, we want to find out whether thermal therapy with MiBo Thermoflo works better than warm compresses and eyelid massage use in the treatment of dry eye caused by MGD. To do this, we will select several patients and will assign them randomly to either the group with thermal therapy with MiBo Thermoflo or to the group with warm compresses and eyelid massage. The Mibo group will receive 3 sessions of thermal therapy at 2 weeks interval and the control group warm compresses and eyelid massage 2 times per day. All subjects will have a follow up of 24 weeks and we will compare results for both groups at the end of the study.

Frequently Asked Questions

What is Efficacy and Safety of Thermic Devices in the Treatment of Meibomian Gland Dysfunction?

Efficacy and Safety of Thermic Devices in the Treatment of Meibomian Gland Dysfunction is a clinical trial registered under NCT03767530. Current status: RECRUITING.

What is the status of NCT03767530?

The current status of NCT03767530 (Efficacy and Safety of Thermic Devices in the Treatment of Meibomian Gland Dysfunction) is: RECRUITING.

When did Efficacy and Safety of Thermic Devices in the Treatment of Meibomian Gland Dysfunction start?

Efficacy and Safety of Thermic Devices in the Treatment of Meibomian Gland Dysfunction started on 2019-09-01.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.